I would most likely consider the neoadjuvant approach. - of course, few things to consider prior to making a decision. 1. How long was the duration between the previous completion of therapy for her first breast cancer? And was previous therapy complete, or rather was incomplete therapy was given? ...

I agree with @Bora Lim. The CALOR trial supports administration of chemotherapy in TNBC patients with a locoregional recurrence. Assuming there is no evidence that the axillary recurrence is biologically different from the breast primary, neoadjuvant chemotherapy will allow you to assess the sensiti...